A182400 Share Price Performance
₩0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
A182400 Community Narratives
There are no narratives available yet.
Recent A182400 News & Updates
No updates
NKMAX CO., Ltd. Key Details
Last Reported Earnings
Mar 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 182.94
- Gross Margin
- 67.40%
- Net Profit Margin
- 149.35%
- Debt/Equity Ratio
- 22.8%
NKMAX CO., Ltd. Competitors
About A182400
- Founded
- 2002
- Employees
- 134
- CEO
- WebsiteView website
NKMAX CO., Ltd. manufactures and sells biological products in South Korea. The company offers anti-cancer immunotherapy treatment that activates the immune cells in body to kill the cancer cells; natural killer cell activity test for cancer patients; NK VUE Kit, an NK cell activity test that measures IFN-gamma released from activated NK cells with small amount of blood; and NK365, a proprietary blend of vitamins, minerals, and agaricus mushroom extract for immune system. It also provides recombinant proteins and monoclonal antibodies; and NK PUPPY, a test that measures dog’s immunity. The company was formerly known as ATGen Co and changed name to NKMAX CO., Ltd. in 2019. The company was founded in 2002 and is headquartered in Seongnam-si, South Korea.
South Korean Market Performance
- 7 Days: -2.0%
- 3 Months: 20.9%
- 1 Year: 26.1%
- Year to Date: 28.6%
Over the last 7 days, the market has dropped 2.0%, driven by pullbacks in the Materials and Information Technology sectors of 7.0% and 1.3%, respectively. As for the longer term, the market has actually risen by 26% in the last year. Earnings are forecast to grow by 22% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading